1 study found for:    9639416 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Low Dose Melphalan and Bortezomib for AML and High-Risk MDS
Conditions: Acute Myelogenous Leukemia;   Myelodysplastic Syndromes
Intervention: Drug: Melphalan, Bortezomib

Indicates status has not been verified in more than two years